TY - JOUR
T1 - Common and species-specific molecular signatures, networks, and regulators of influenza virus infection in mice, ferrets, and humans
AU - Forst, Christian V.
AU - Martin-Sancho, Laura
AU - Tripathi, Shashank
AU - Wang, Guojun
AU - Dos Anjos Borges, Luiz Gustavo
AU - Wang, Minghui
AU - Geber, Adam
AU - Lashua, Lauren
AU - Ding, Tao
AU - Zhou, Xianxiao
AU - Carter, Chalise E.
AU - Metreveli, Giorgi
AU - Rodriguez-Frandsen, Ariel
AU - Urbanowski, Matthew D.
AU - White, Kris M.
AU - Stein, David A.
AU - Moulton, Hong
AU - Chanda, Sumit K.
AU - Pache, Lars
AU - Shaw, Megan L.
AU - Ross, Ted M.
AU - Ghedin, Elodie
AU - García-Sastre, Adolfo
AU - Zhang, Bin
N1 - Funding Information:
This work was funded by National Institutes of Health grant R21 AI149013 (to C.V.F.), National Institutes of Health grant U01 AI111598 (to B.Z. and E.G.), National Institutes of Health grant U19 AI106754 (to A.G.-S., M.L.S., and S.K.C.), and National Institutes of Health grant U19 AI135972 (to A.G.-S., L.P., and S.K.C). This work was also funded in part by the Division of Intramural Research (DIR) of NIAID/NIH (to E.G.) and by NIAID grants U19AI142733 and U19AI168631, CRIPT (Center for Research on Influenza Pathogenesis and Transmission), and NIAID-funded Center of Excellence for Influenza Research and Response (CEIRR; contract #75N93021C00014) to A.G.-S. S.T. is supported by the DBT-Wellcome Trust India Alliance Intermediate Fellowship (IA/I/18/1/503613). The A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7 Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories, and Merck, outside of the reported work. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7 Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, Paratus, CureLab Oncology, CureLab Veterinary, Synairgen, and Pfizer, outside of the reported work.
Publisher Copyright:
Copyright © 2022 The Authors, some rights reserved;
PY - 2022/10
Y1 - 2022/10
N2 - Molecular responses to influenza A virus (IAV) infections vary between mammalian species. To identify conserved and species-specific molecular responses, we perform a comparative study of transcriptomic data derived from blood cells, primary epithelial cells, and lung tissues collected from IAV-infected humans, ferrets, and mice. The molecular responses in the human host have unique functions such as antigen processing that are not observed in mice or ferrets. Highly conserved gene coexpression modules across the three species are enriched for IAV infection–induced pathways including cell cycle and interferon (IFN) signaling. TDRD7 is predicted as an IFN-inducible host factor that is up-regulated upon IAV infection in the three species. TDRD7 is required for antiviral IFN response, potentially modulating IFN signaling via the JAK/STAT/IRF9 pathway. Identification of the common and species-specific molecular signatures, networks, and regulators of IAV infection provides insights into host-defense mechanisms and will facilitate the development of novel therapeutic interventions against IAV infection.
AB - Molecular responses to influenza A virus (IAV) infections vary between mammalian species. To identify conserved and species-specific molecular responses, we perform a comparative study of transcriptomic data derived from blood cells, primary epithelial cells, and lung tissues collected from IAV-infected humans, ferrets, and mice. The molecular responses in the human host have unique functions such as antigen processing that are not observed in mice or ferrets. Highly conserved gene coexpression modules across the three species are enriched for IAV infection–induced pathways including cell cycle and interferon (IFN) signaling. TDRD7 is predicted as an IFN-inducible host factor that is up-regulated upon IAV infection in the three species. TDRD7 is required for antiviral IFN response, potentially modulating IFN signaling via the JAK/STAT/IRF9 pathway. Identification of the common and species-specific molecular signatures, networks, and regulators of IAV infection provides insights into host-defense mechanisms and will facilitate the development of novel therapeutic interventions against IAV infection.
UR - http://www.scopus.com/inward/record.url?scp=85139342778&partnerID=8YFLogxK
U2 - 10.1126/sciadv.abm5859
DO - 10.1126/sciadv.abm5859
M3 - Article
C2 - 36197970
AN - SCOPUS:85139342778
SN - 2375-2548
VL - 8
JO - Science advances
JF - Science advances
IS - 40
M1 - eabm5859
ER -